RxDoctor Payments DataLook up a doctor →

Joleen Volz, PA

Physician Assistant · Corsicana, TXNPI 1487711347

Payments from drug & device makers

$50,572in general payments, 2019–2025

Across 576 payments — averaging $87.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arcutis Biotherapeutics, Inc.$13K
  • Sun Pharmaceutical Industries Inc.$6K
  • Incyte Corporation$6K
  • UCB, Inc.$5K
  • E.r. Squibb & Sons, L.L.C.$4K
  • LEO Pharma Inc.$3K
  • plus $13K from 24 others

What the payments were for

  • Consulting fees$22,24944%
  • Speaking & faculty fees$3,8408%
  • Travel & lodging$4,4549%
  • Food & beverage$19,18138%
  • Education$8472%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,572 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$206,376
Medicare patients
637
Services billed
4,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab22$457,384
Humira(Cf) PenAdalimumab16$186,745
Cosentyx Unoready PenSecukinumab12$172,925
Dupixent SyringeDupilumab14$52,277
Dupixent PenDupilumab12$50,896
ZoryveRoflumilast11$9,249
Ketoconazole224$3,798
Clobetasol Propionate87$3,462
Betamethasone Valerate63$2,086
Tacrolimus15$1,863
Triamcinolone Acetonide88$1,278
Metronidazole21$1,120
Doxycycline Hyclate36$842
Glycopyrrolate17$796
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet33$753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,778$457,38422 claims
Arcutis Biotherapeutics, Inc.Zoryve$12,723$9,24911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Corsicana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →